TGFB1 and cancer: Numerous anti-cancer pharmacological interventions targeting TGF-β have undergone pre-clinical and clinical stage studies; however, although several anti-TGF-β-based immunotherapies were effective in preclinical trails (247–249), the results of subsequent clinical trials were disappointing, due to low efficacy and safety issues (250).